5-(bromomethyl)-4-methyl-2-(methylthio)pyrimidine | 135645-54-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 5-(bromomethyl)-4-methyl-2-(methylthio)pyrimidine
• 英文别名: 5-(bromomethyl)-4-methyl-2-methylsulfanylpyrimidine
• CAS: 135645-54-4
• 化学式: C₇H₉BrN₂S
• 分子量: 233.132
• InChiKey: LLWVMWRPEYQMKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(bromomethyl)-4-methyl-2-(methylthio)pyrimidine 在 碳酸氢钠 、 二甲基亚砜 作用下， 以63%的产率得到5-formyl-4-methyl-2-methylthiopyrimidine
  参考文献：
  名称：

  Highly regioselective bromination reactions of polymethylpyrimidines

  摘要：

  4,5-Dimethyl- and 4,5,6-trimethyl-substituted pyrimidines are brominated at C5-Me with NBS in CCl4 and at C4(6)-Me with bromine in acetic acid to give the corresponding bromomethyl derivatives in a high yield. The remaining methyl group(s) can also be brominated with high regioselectivity. The 2-methylthio substituent is not oxidized under these conditions.

  DOI：

  10.1021/jo00019a028
• 作为产物：
  描述：

  5-甲基-2-(甲硫基)嘧啶 在 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 0.67h， 生成 5-(bromomethyl)-4-methyl-2-(methylthio)pyrimidine
  参考文献：
  名称：

  Highly regioselective bromination reactions of polymethylpyrimidines

  摘要：

  4,5-Dimethyl- and 4,5,6-trimethyl-substituted pyrimidines are brominated at C5-Me with NBS in CCl4 and at C4(6)-Me with bromine in acetic acid to give the corresponding bromomethyl derivatives in a high yield. The remaining methyl group(s) can also be brominated with high regioselectivity. The 2-methylthio substituent is not oxidized under these conditions.

  DOI：

  10.1021/jo00019a028

文献信息

• [EN] PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2021257353A1

  公开（公告）日：2021-12-23

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

  本发明提供了一种式(I)的化合物，以及包括一种或多种所述化合物的药物组合物，并且使用所述化合物治疗或预防可能受益于抑制血浆激肽酶的一种或多种疾病状态的方法，包括遗传性血管性水肿、葡萄膜炎、后部葡萄膜炎、湿性老年性黄斑水肿、糖尿病性黄斑水肿、糖尿病视网膜病变和视网膜静脉阻塞。这些化合物是血浆激肽酶的选择性抑制剂。